Live News EQUITY FLASH L impact Oct 26, 2026, 11:14 AM UTC MacroGenics Reports Lorigerlimab Response in Phase 2 Tumor Study The study evaluated lorigerlimab in clear-cell gynecologic tumors. MGNX SquawkNews Desk